1. Low-Molecular-Weight Collagen Peptide Ameliorates Osteoarthritis Progression through Promoting Extracellular Matrix Synthesis by Chondrocytes in a Rabbit Anterior Cruciate Ligament Transection Model
- Author
-
Jin-Hee Lee, Hee-Chul Chung, Mun-Hoe Lee, Hyeong-Min Kim, and Do-Un Kim
- Subjects
Male ,medicine.medical_specialty ,Anterior cruciate ligament ,H&E stain ,Type II collagen ,Osteoarthritis ,Applied Microbiology and Biotechnology ,Chondrocyte ,Extracellular matrix ,Chondrocytes ,Internal medicine ,Matrix Metalloproteinase 13 ,Synovial Fluid ,medicine ,Animals ,Humans ,Synovial fluid ,Aggrecans ,Anterior Cruciate Ligament ,Collagen Type II ,Cells, Cultured ,Chemistry ,Cartilage ,General Medicine ,medicine.disease ,Extracellular Matrix ,Molecular Weight ,Disease Models, Animal ,medicine.anatomical_structure ,Endocrinology ,Cytokines ,Collagen ,Rabbits ,Peptides ,Biotechnology - Abstract
This study examined whether the oral administration of low-molecular-weight collagen peptide (LMCP) containing 3% Gly-Pro-Hyp with >15% tripeptide (Gly-X-Y) content could ameliorate osteoarthritis (OA) progression using a rabbit anterior cruciate ligament transection (ACLT) model of induced OA and chondrocytes isolated from a patient with OA. Oral LMCP administration (100 or 200 mg/kg/day) for 12 weeks ameliorated cartilage damage and reduced the loss of proteoglycan compared to the findings in the ACLT control group, resulting in dose-dependent (p < 0.05) improvements of the OARSI score in hematoxylin & eosin (H&E) and Safranin O staining. In microcomputed tomography analysis, LMCP also significantly (p < 0.05) suppressed the deterioration of the microstructure in tibial subchondral bone during OA progression. The elevation of IL-1βand IL-6 concentrations in synovial fluid following OA induction was dose-dependently (p < 0.05) reduced by LMCP treatment. Furthermore, immunohistochemistry illustrated that LMCP significantly (p < 0.05) upregulated type II collagen and downregulated matrix metalloproteinase-13 in cartilage tissue. Consistent with the in vivo results, LMCP significantly (p < 0.05) increased the mRNA expression of COL2A1 and ACAN in chondrocytes isolated from a patient with OA regardless of the conditions for IL-1βinduction. These findings suggest that LMCP has potential as a therapeutic treatment for OA that stimulates cartilage regeneration.
- Published
- 2021
- Full Text
- View/download PDF